Pfizer reported third-quarter 2026 results on November 3 that exceeded the company’s expectations. The company’s commercial performance globally and continued financial discipline led to it raising its financial outlook for the year. With commercial momentum building and a robust slate of expected catalysts ahead, the company is focused on returning to growth toward the end of the decade.

See below for key highlights. More details on Pfizer’s third-quarter 2026 earnings results and financial guidance can be found here.

Q3 2026 / Year-to-Date Highlights as of Nov. 3, 2026

  • Launched and acquired products[i]drove growth: Strong revenue from these products grew 32% operationally, contributing $3.8 billion to Pfizer’s total revenue of $16.6 billion in the third quarter.
  • Key brands delivered: Medicines to treat blood clots, cancer and migraine were important contributors to Pfizer’s quarterly results.
  • Robust late-stage pipeline advanced: Key milestones since our last quarterly earnings included two regulatory decisions, one pivotal readout and eight pivotal study starts while sharing new data at recent medical congresses. Pfizer has invested $8.3 billion in its R&D in the first nine months of this year across its four therapeutic focus areas: Oncology, Vaccines, Inflammation & Immunology and Internal Medicine.
  • Capital went back to shareholders: Returned $7.3 billion to shareholders through quarterly cash dividends in the first nine months of 2026, a core part of our capital allocation strategy.
  • Productivity programs are delivering: Ongoing productivity improvements are driving efficiency and enabling continued investment in Pfizer’s robust pipeline.
  • Raised full-year guidance[ii]: Based on strong year-to-date performance and continued confidence in the business, Pfizer now expects 2026 revenue of $62.0 billion to $64.0 billion and Adjusted diluted EPS of $2.95 to $3.05.

“I’m pleased with another strong quarter for Pfizer. Our excellent commercial execution, including 32% operational revenue growth in the quarter for our launched and acquired products, shows the underlying strength of our business. Financial discipline and ongoing productivity improvement are driving efficiency and contributing favorably toward our margins. And, with continued progress of our high-value R&D programs, we believe we’re on a pathway to the next stage of meaningful growth.” said Dr. Albert Bourla, Chairman and Chief Executive Officer, during the company's conference call with investment analysts.

Pfizer's Critical R&D Milestones

Forward-looking statements included herein, including those related to our anticipated operating and financial performance, including our financial guidance, growth, our productivity programs, our product and pipeline advancements and our efforts to return value to shareholders, speak only as of the original date they were made and are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at pfizer.com and the SEC’s website. Also reference Pfizer’s third quarter 2026 earnings release for additional information regarding our financial guidance details and assumptions.

[i] Launched and Acquired Products’ represent select recently launched and acquired products, including new indications. Launched products primarily include Prevnar 20 (Pediatrics), Abrysvo (Older Adult / Maternal), Elrexfio, Cibinqo, Talzenna, Litfulo, Ngenla, Hympavzi, Penbraya Adolescent, and Lorbrena (added Q1-26); and acquired products primarily include Padcev, Adcetris, Tukysa, Tivdak, Nurtec ODT/

Vydura, and Velsipity.

[ii] Please see Pfizer’s Q3 2026 earnings release for additional details and assumptions regarding Pfizer’s 2026 financial guidance, including the definition of Adjusted Diluted EPS. This document includes certain financial measures that were not prepared in accordance with U.S. generally accepted accounting principles (GAAP). Additional information regarding non-U.S. GAAP financial measures can be found in Pfizer's earnings release furnished with Pfizer’s Current Report on Form 8-K dated November 3, 2026.